Highlighting Genprex’s Medical Advisors on National Doctors’ Day

March 30 marks National Doctors’ Day, an annual holiday when we can all acknowledge and show appreciation for our physicians who help save lives everywhere. During the current COVID-19 pandemic, we especially want to take the time to recognize and honor our doctors who are on the front lines, finding a cure and risking their lives to help patients.

We thank our medical professionals who continue to strive and make medical advancements for the betterment of society, and as benefactors of the medical field, we thank all doctors everywhere we have dedicated their lives to improving the quality of life for people around the world. 

At Genprex, we’re at the forefront in the fight against cancer and diabetes with cutting-edge gene therapies. The viability and success of those life-saving technologies wouldn’t be possible without our industry-leading team of medical advisors. This #NationalDoctorsDay, we want to highlight the members of our Scientific Advisory Board (SAB) that power Genprex and thank them for all that they’ve done – and continue to do – to improve patient outcomes. 

As the Chairman of our SAB, Dr. Jack A. Roth plays a crucial role in Genprex’s success. An internationally recognized cancer specialist and pioneering oncologist, Dr. Roth is Professor and Distinguished Chair of Thoracic Surgery, Professor of Molecular & Cellular Oncology, Director of the Keck Center for Innovative Cancer Therapies, and Chief of Section of Thoracic Molecular Oncology at The University of Texas MD Anderson Cancer Center. One of the pioneers in the usage of DNA as a therapeutic agent, he has authored more than 600 peer-reviewed journal articles. As the inventor of our key intellectual property, his 20+ years of experience are indispensable.

Joining us from Harvard Medical School, Dr. Pasi Antero Jänne is also a valuable member of our SAB. As a Co-Leader of the Lung Cancer Program at Dana-Farber Harvard Cancer Center, an Associate Professor of Medicine at Harvard Medical School, and a clinician at Dana-Farber Cancer Institute Lowe Center for Thoracic Oncology, Dr. Jänne is a leading researcher in the field of medical oncology. His research on epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer and their impact on the efficacy of EGFR-targeted therapeutic agents, as well as mechanisms of sensitivity and resistance targeted cancer therapies, greatly impacts the work we do at Genprex to deliver next-generation cancer treatments.

Dr. Tony Mok brings a wealth of knowledge in lung cancer to the Company. He is the Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong in Prince of Wales Hospital in Hong Kong and a member of the American Society of Clinical Oncology (ASCO) Board of Directors. He previously served as President of the International Association for the Study of Lung Cancer (IASLC), Vice-Secretary General of the Chinese Society of Clinical Oncology (CSCO), and is Co-founder of the Lung Cancer Research Group, a multicenter organization serving the Asian-Pacific region. He has published more than 130 articles in peer reviewed journals, including the prestigious New England Journal of Medicine, Science, Lancet, and Journal of Clinical Oncology. Additionally, Dr. Mok is the Associate Editor of the Journal of Thoracic Oncology, Clinical Lung Cancer, and Asia Pacific Journal of Clinical Oncology. His research focuses on biomarker and molecular targeted therapy in lung cancer.

Dr. George Simon is a Professor of Medicine and Section Chief, Translational Research, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. He specializes in treating patients with lung cancer, mesothelioma, and thymoma. Dr. Simon’s research in developing optimal treatment strategies based on a deep understanding of a patient’s tumor’s molecular profile aligns well with our focus at Genprex. He has been the recipient of numerous annual Castle Connolly Top Doctor awards, Amercia’s Top Doctor awards, and Houston’s Top Doctor awards, and his research has been published in over 50 peer-reviewed journals.

Together, Doctors Roth, Jänne, Mok and Simon are absolutely crucial to our mission at Genprex. With their help, we have become a leader in the gene therapy field, offering hope to the millions of people struggling with cancer and diabetes around the world. We’re always grateful for their work, but today is the perfect time to say it: Thank you, Doctors!